Results 111 to 120 of about 40,102 (155)

Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease. [PDF]

CNS Drugs
Frank S, Testa CM, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Whaley J, Gross N, Chaijale N, Barash S, Gordon MF, Huntington Study Group/ARC-HD Investigators and Coordinators.   +12 more
europepmc   +1 more source

Integrative determination of atomic structure of mutant huntingtin exon 1 fibrils implicated in Huntington disease. [PDF]

Nat Commun
Bagherpoor Helabad M, Matlahov I, Kumar R, Daldrop JO, Jain G, Weingarth M, van der Wel PCA, Miettinen MS.   +7 more
europepmc   +1 more source

Age- and disease-related autophagy impairment in Huntington disease: New insights from direct neuronal reprogramming. [PDF]

Aging Cell
Luo C, Yang J.
europepmc   +1 more source

Gastrointestinal Hemorrhage and Diffuse Bowel Dilation in Huntington Disease. [PDF]

ACG Case Rep J
Kolachana S, Motwani K, Sakiani S.
europepmc   +1 more source

Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease. [PDF]

Neurol Ther
Frank S, Anderson KE, Fernandez HH, Hauser RA, Claassen DO, Stamler D, Factor SA, Jimenez-Shahed J, Barkay H, Wilhelm A, Alexander JK, Chaijale N, Barash S, Savola JM, Gordon MF, Chen M.   +15 more
europepmc   +1 more source

Huntington disease alters the actionable information in plasma extracellular vesicles. [PDF]

Clin Transl Med
Neueder A, Nitzschner P, Wagner R, Hummel J, Hoschek F, Wagner M, Abdelmoez A, von Einem B, Landwehrmeyer GB, Tabrizi SJ, Orth M.   +10 more
europepmc   +1 more source

Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments: A Decision-Modeling Analysis. [PDF]

Neurol Clin Pract
Guzauskas GF, Tabrizi SJ, Long JD, Arnesen A, Hamilton JL, Claassen DO, Munetsi LR, Malik S, Rodríguez-Santana I, Ali TM, Zhang F.   +10 more
europepmc   +1 more source